Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A289VV1
Tue, 13.09.2022
HAEMATO AG
1st HY 2022: Declining sales and earnings development as expected due to
discontinuation of sales with corona rapid tests, earnings forecast
confirmed, price target reduced to EUR 37.55 (previously: EUR 49.00) after
increase of risk-free interest rate; rating: BUY
As expected, HAEMATO AG showed an overall decline in business development
in the f [ … ]
Tue, 13.09.2022
HAEMATO AG
1st HY 2022: Declining sales and earnings development as expected due to
discontinuation of sales with corona rapid tests, earnings forecast
confirmed, price target reduced to EUR 37.55 (previously: EUR 49.00) after
increase of risk-free interest rate; rating: BUY
As expected, HAEMATO AG showed an overall decline in business development
in the f [ … ]
Thu, 18.08.2022
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 43,00 auf EUR 35,00.
Zusammenfassung:
Die vorläufigen Halbjahreszahlen lagen nahe an unseren Schätzungen, blieben
jedoch hinter den Vorjahre [ … ]
Thu, 18.08.2022
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 43,00 auf EUR 35,00.
Zusammenfassung:
Die vorläufigen Halbjahreszahlen lagen nahe an unseren Schätzungen, blieben
jedoch hinter den Vorjahre [ … ]
Wed, 17.08.2022
HAEMATO AG
___________________________________________________________________________
HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022
In the second quarter of 2022, preliminary IFRS consolidated revenues increased by around 22% to EUR 66.4 million c [ … ]
Wed, 17.08.2022
HAEMATO AG
___________________________________________________________________________
HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022
In the second quarter of 2022, preliminary IFRS consolidated revenues increased by around 22% to EUR 66.4 million c [ … ]
Mon, 23.05.2022
HAEMATO AG
______________________________________________________________________________
HAEMATO AG publishes figures for Q1 2022: further improvement in EBIT margin and confirmation of guidance
- Group turnover decreases to EUR 54.6 million (EUR 73.9 million in Q1-2021) due to product portfolio adjustment
- Group EBITDA of EUR 2.3 million (previous year: [ … ]
Tue, 03.05.2022
HAEMATO AG
______________________________________________________________________________
HAEMATO AG: Dividend of EUR 1.10
Berlin, May 3, 2022 - At today's balance sheet meeting, the annual financial statements 2021 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Boa [ … ]
Fri, 08.04.2022
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 50,00 auf EUR 43,00.
Zusammenfassung:
Die vorläufigen Zahlen verdeutlichen das Aufwärtspotenzial des sich
entwickelnden Geschäftsmodell [ … ]
Tue, 05.04.2022
HAEMATO AG
Preliminary figures 2021: Revenues in line with expectations, earnings
exceeded; GBC forecasts for 2022 and 2023 adjusted to company guidance;
High upside potential in the self-pay market; Target price EUR47.50; BUY
rating
On 30 March 2022, HAEMATO AG published the preliminary figures for the past
financial year 2021. As expected, the company re [ … ]